# Inge M. van der Sluis

Source: https://onco.cc/people/inge-van-der-sluis/  
OnCo record `inge-van-der-sluis` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Dutch paediatric oncologist who led the study showing that adding one course of blinatumomab to chemotherapy sharply improves survival for babies with KMT2A-rearranged leukaemia.

## Summary

Inge van der Sluis is a paediatric oncologist at the Princess Máxima Center in Utrecht. She was first author of the 2023 New England Journal of Medicine report of the Interfant pilot study in which a single 28-day course of the bispecific antibody blinatumomab added to Interfant-06 chemotherapy gave two-year disease-free survival of over 80 percent in infants with KMT2A-rearranged acute lymphoblastic leukaemia, far higher than historical controls. She also studies asparaginase pharmacology.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: paediatric; leukaemia; immunotherapy; trialist
- Role: Paediatric oncologist, Princess Máxima Center for Pediatric Oncology
- Specialisms: Infant leukaemia; Immunotherapy in paediatric leukaemia; Asparaginase

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)](https://onco.cc/cancers/all-infant/)
- institutions: [Princess Máxima Center for Pediatric Oncology](https://onco.cc/institutions/princess-maxima/)
- key papers: [Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia](https://onco.cc/key-papers/paper-blinatumomab-infant-all-van-der-sluis-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/inge-van-der-sluis.json